Table 3.

Cancers with an MSI-H frequency less than 2%

Tumor typeFrequency, % (n)Study
Skin (squamous cell)0% (30), 0% (56)Reuschenbach et al. (89)a
Skin (basal cell)0% (53), 2% (104)Reuschenbach et al. (89)a
Prostate1% (79)Burger et al. (90)
Lung0% (80), 2% (55)Okuda et al. (91), Ninomiya et al. (92)
Osteosarcoma0% (68)Entz-Werle et al. (93)
Glioblastoma0% (109)Martinez et al. (94)
Pancreatic ductal adenocarcinoma0%–2% (338)Laghi et al (95)
Breast0% (267), 0% (34), 0% (52), 1% (100)Anbazhagan et al. (96), Adem et al. (97), Kuligina et al. (98), Toyama et al. (99)
Bladder1% (84)Catto et al. (100)
Testicular germ cell0% (100)Mayer et al. (70)
  • aThe first percentage given resulted from looking at a series of cases with three mononucleotide markers (BAT25, BAT26, and CAT25).The second number was derived by the authors by summing the results of several other studies, not all of which defined MSI-H in a manner consistent with the Bethesda guidelines.